英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字,中文词皆可:

testifying    音标拼音: [t'ɛstəf,ɑɪɪŋ]
Testify \Tes"ti*fy\, v. i. [imp. & p. p. {Testified}; p. pr. &
vb. n. {Testifying}.] [OF. testifier, L. testificari; testis
a witness -ficare (in comp.) to make. See {-fy}, and cf.
{Attest}, {Contest}, {Detest}, {Protest}, {Testament}.]
1. To make a solemn declaration, verbal or written, to
establish some fact; to give testimony for the purpose of
communicating to others a knowledge of something not known
to them.
[1913 Webster]

Jesus . . . needed not that any should testify of
man, for he knew what was in man. --John ii. 25.
[1913 Webster]

2. (Law) To make a solemn declaration under oath or
affirmation, for the purpose of establishing, or making
proof of, some fact to a court; to give testimony in a
cause depending before a tribunal.
[1913 Webster]

One witness shall not testify against any person to
cause him to die. --Num. xxxv.
30.
[1913 Webster]

3. To declare a charge; to protest; to give information; to
bear witness; -- with against.
[1913 Webster]

O Israel, . . . I will testify against thee. --Ps.
l. 7.
[1913 Webster]

I testified against them in the day wherein they
sold victuals. --Neh. xiii.
15.
[1913 Webster]


请选择你想看的字典辞典:
单词字典翻译
Testifying查看 Testifying 在百度字典中的解释百度英翻中〔查看〕
Testifying查看 Testifying 在Google字典中的解释Google英翻中〔查看〕
Testifying查看 Testifying 在Yahoo字典中的解释Yahoo英翻中〔查看〕





安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Adstiladrin: Uses, Dosage, Side Effects Warnings - Drugs. com
    Adstiladrin (nadofaragene firadenovec-vncg) is a gene therapy used to treat high-risk Bacillus CalmetteGuérin (BCG)-unresponsive non-muscle invasive bladder cancer Includes Adstiladrin side effects, interactions and indications
  • Ferring Announces Update to NCCN Guidelines Expanding . . .
    About ADSTILADRIN ADSTILADRIN ® (nadofaragene firadenovec-vncg) is an FDA-approved intravesical non-replicating gene-therapy for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors (±Ta T1)
  • Package Insert - ADSTILADRIN
    ADSTILADRIN® is indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-Muscle Invasive Bladder Cancer (NMIBC) with carcinoma in situ (CIS
  • NCCN upgrades recommendation for nadofaragene firadenovec in . . .
    An update to the 2026 National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology has elevated the recommendation for nadofaragene firadenovec-vncg (Adstiladrin) in select patients with BCG-unresponsive non–muscle invasive bladder cancer (NMIBC), Ferring Pharmaceuticals announced in a news release 1
  • Nadofaragene firadenovec-vncg (urinary bladder route)
    Description Nadofaragene Firadenovec-vncg is used to treat patients with high-risk Bacillus Calmette-Guerin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with a tumor type called carcinoma in situ (CIS) with or without papillary tumors This medicine is to be used only by or under the direct supervision of a doctor
  • FDA Approval Summary: Nadofaragene Firadenovec-vncg for . . .
    Abstract On December 16, 2022, the FDA approved the adenoviral vector-based gene therapy nadofaragene firadenovec-vncg (brand name Adstiladrin) for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) The product represents the first approved adenoviral vector-based gene therapy and
  • Adstiladrin (Nadofaragene Firadenovec-vncg): Uses, Side . . .
    What is Adstiladrin (Nadofaragene Firadenovec-vncg) Used For? Adstiladrin (Nadofaragene Firadenovec-vncg) is a gene therapy specifically indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors
  • ADSTILADRIN® (nadofaragene firadenovec-vncg) | For HCP
    Nadofaragene firadenovec- vncg (ADSTILADRIN) is A recommended treatment option: In the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)* and the AUA SUO Guidelines1 By the International Bladder Cancer Group (IBCG) for high-risk NMIBC after BCG failure for those seeking to avoid radical cystectomy 2
  • Package Insert - ADSTILADRIN
    ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors (1)
  • FDA approves first adenoviral vector-based gene therapy for . . .
    The recommended nadofaragene firadenovec-vncg dose is 75 mL at a concentration of 3 x 1011 vp mL instilled once every three months into the bladder via a urinary catheter





中文字典-英文字典  2005-2009